LONDON and NEW YORK, April 05, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant. | April 5, 2023
LONDON and NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused.
LONDON and NEW YORK, April 04, 2023 OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant. | April 4, 2023
LONDON and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing